Literature DB >> 25082289

Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity.

Stacy R Lindborg1, Charles C Persinger2, Andreas Sashegyi2, Craig Mallinckrodt2, Stephen J Ruberg2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25082289     DOI： 10.1038/nrd3681-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

1.  The malignant melanoma landscape.

Authors:  Rachel M Webster; Samuel E Mentzer
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694
  1 in total
  3 in total

1.  The analysis of the market success of FDA approvals by probing top 100 bestselling drugs.

Authors:  Jaroslaw Polanski; Jacek Bogocz; Aleksandra Tkocz
Journal:  J Comput Aided Mol Des       Date:  2016-04-28       Impact factor: 3.686

2.  Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin.

Authors:  Jing Fan Yang; Xun Gong; Naveed A Bakh; Kelley Carr; Nelson F B Phillips; Faramarz Ismail-Beigi; Michael A Weiss; Michael S Strano
Journal:  Diabetes       Date:  2020-03-09       Impact factor: 9.461

3.  The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.

Authors:  T Burt; K S Button; Hhz Thom; R J Noveck; M R Munafò
Journal:  Clin Transl Sci       Date:  2017-07-04       Impact factor: 4.689
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.